ReviewCancers2022
Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Low-grade B-cell non-Hodgkin lymphoma in the sternocleidomastoid muscle: a case report and review of literature.Frontiers in oncology · 2026Article
- Primary Pulmonary Marginal Zone Lymphoma Presenting With Asymptomatic Lung Consolidation.Case reports in pulmonology · 2026Article
- Non-gastric mucosa-associated lymphoid tissue lymphomas: a narrative review of pathogenesis, diagnosis, and treatment strategies.Annals of translational medicine · 2025Review
- Initial Treatment Strategies Show No Survival Difference in Early-Stage Salivary Gland Mucosa-Associated Lymphoid Tissue Lymphoma.Journal of multidisciplinary healthcare · 2025Article
- Rare Orbital Involvement Originating from Extranodal Marginal Zone Lymphoma.Medicina (Kaunas, Lithuania) · 2024Article
- The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma.Biomedicines · 2024Review
- Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018).Cancer medicine · 2023Article
- Mucosa-Associated Lymphoid Tissue Lymphoma of the Sublingual Salivary Gland: A Case Report.Cureus · 2023Article
- Review of lymphoma in the duodenum: An update of diagnosis and management.World journal of gastroenterology · 2023Review
- A Phase II Study ofClinical Medicine Insights. Oncology · 2023Article
- Intestinal Mucosa-Associated Lymphoid Tissue Lymphoma Transforming into Diffuse Large B-Cell Lymphoma in a Young Adult Patient with Neurofibromatosis Type 1: A Case Report.Medicina (Kaunas, Lithuania) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal marginal zone lymphoma (EMZL) encompasses a subgroup of non-Hodgkin lymphomas that often present with localized involvement and may manifest in a diversity of organs and tissues. EMZL pathogenesis is in some cases linked to chronic inflammation/infection, which may impose additional diagnostic and clinical challenges. The most studied and established connection is the presence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.